PT -期刊文章盟Hisatomo Kowa AU - Tohko Miyawaki AU -吴克群Sekiguchi AU - Fumio神田盟Tatsushi户田拓夫TI -治疗类似中风发作在食物药物(P04.162) DP - 2012年4月25日TA -神经病学PG - P04.162 P04.162 VI - 78 IP - 1补充4099 - //www.ez-admanager.com/content/7首页8/1_Supplement/P04.162.short 4100 - //www.ez-admanager.com/content/78/1_Supplement/P04.162.full所以Neurology2012 4月25日;78 AB -目的:测试是否药物不良反应,自由基的清道夫,能防止中风病灶扩散看见病人。背景类似中风的米拉引起很多症状包括轻偏瘫,改变意识、偏盲、癫痫和剧烈的头痛。重复类似中风发作可以逐步损害大脑,导致脑萎缩,导致视力丧失、运动和痴呆的问题。但是,没有治疗对预防类似中风发作已经建立。药物不良反应是一个神经剂用于帮助神经系统急性脑缺血后恢复的目的。它作为一种强有力的抗氧化剂,大力进行清除自由基,防止氧化应激和神经细胞凋亡。设计/方法:三个米拉mtDNA突变患者np 3243一直在评估临床症状,而图像顺序。六个类似中风发作观察在这些情况下,四个精氨酸处理,抗癫痫药物。药物不良反应是应用于两集连续14天期间除了常规治疗。Results: Cortical lesions suffering from stroke-like episodes showed severe atrophy in two months after episode in case of no edaravone treatment. Most symptoms caused by morbid cortices were remained for a long time. By contrast, when treated with edaravone within one week after onset of episode, cortical atrophy was avoided, and cortical functions were recovered very well. Controls of epilepsy was relatively easier in episodes treated with edaravone compared to edaravone unused attacks.Conclusions: Our experience suggests that edaravone could prevent brain atrophy of lesions suffering from stroke-like episodes. Clinical trial in large-scale is necessary to conclude the efficiency of edaravone on stroke-like episodes of MELAS.Disclosure: Dr. Kowa has nothing to disclose. Dr. Miyawaki has nothing to disclose. Dr. Sekiguchi has nothing to disclose. Dr. Kanda has nothing to disclose. Dr. Miyawaki has nothing to disclose.Wednesday, April 25 2012, 07:30 am-12:00 pm